A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies

Trial Profile

A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs VS 4718 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Verastem Oncology
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
    • 25 Jul 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top